Clinical trial
Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or…
NCT00360438 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00360438 |
|---|---|
| Title | Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS |
| Official title | Pharmacokinetic Evaluation of Rasburicase Dosed for 5 Consecutive Days as Uricolytic Therapy in Adult Patients With Leukemia and/or Lymphoma at High or Potential Risk of Tumor Lysis Syndrome (TLS) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Sanofi Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma, Tumor Lysis Syndrome |
| Intervention type | Drug |
| Interventions | Rasburicase |
| Enrollment | 18 |
| Start date | Jul 1, 2006 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Aug 4, 2006 |
| Last update posted | Aug 1, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: